Metformin Arena (Metformin Hydrochloride)

Metformin works mainly by inhibiting mitochondrial complex I, which reduces hepatic gluconeogenesis. It also activates AMP‑activated protein kinase (AMPK), enhancing peripheral glucose uptake and insulin sensitivity, thereby lowering overall blood glucose without stimulating insulin release.

The dosage of Metformin Arena is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Metformin Arena should be used in pregnancy or while breastfeeding only if the potential benefits outweigh the possible risks. The decision must be made by a qualified healthcare provider after evaluating the specific circumstances of the mother and fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin belongs to the biguanide class and is often preferred as first‑line therapy because it does not cause weight gain and has a low risk of hypoglycemia when used alone. Compared with sulfonylureas or insulin, it works by improving insulin sensitivity rather than stimulating insulin secretion.

Metformin Arena should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Metformin Arena is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically directed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, hypoxia, or acute illness. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin Arena is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with known hypersensitivity to metformin or any component of the formulation.